Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura

J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1730-2. doi: 10.1136/jnnp.2005.063750.

Abstract

This study examined the efficacy of lamotrigine in the prevention of migraine aura. Fifty nine patients suffering from migraine with aura received lamotrigine in a controlled three year prospective open study. Treatment response was defined as a reduction of aura frequency each month by at least 50%. Primary endpoint was reached by three quarters of the patients. Lamotrigine significantly reduced both frequency of migraine aura (mean, 1.5 (SD, 0.6) each month before v 0.4 (0.7) after treatment; p < 0.001) and aura duration (mean, 27 (SD, 11) minutes before v 8 (14) after treatment; p < 0.001). Furthermore, more than three quarters of those patients with a reduction of aura symptoms experienced a significant reduction of frequency of migraine attacks (mean, 2.1 (SD, 1.0) each month before v 1.2 (1.1) after treatment; p < 0.001). Lamotrigine was highly effective in reducing migraine aura and migraine attacks. The strong correlation between reduction of aura symptoms and migraine attacks stresses the potential role of aura-like events and possibly cortical spreading depression as a trigger for trigeminal vascular activation, and subsequently the development of migraine headaches.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Analgesics / therapeutic use*
  • Female
  • Humans
  • Lamotrigine
  • Male
  • Middle Aged
  • Migraine with Aura / drug therapy*
  • Migraine with Aura / pathology
  • Severity of Illness Index
  • Treatment Outcome
  • Triazines / therapeutic use*

Substances

  • Analgesics
  • Triazines
  • Lamotrigine